Oxcarbazepine or Eslicarbazepine Metabolite (MHD)
Optimize drug therapy and monitor patient adherence.
New York DOH Approval Status
Timing of specimen collection: Pre-dose (trough) draw - At steady state concentration.
Plain red. Also acceptable: Lavender (K2 or K3EDTA) or pink (K2 EDTA).
Separate serum or plasma from cells within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)
Whole blood. Gel separator tubes, light blue (citrate), or yellow (SPS or ACD solution).
After separation from cells: Ambient: 6 weeks; Refrigerated: 6 weeks; Frozen: 3 months (avoid repeated freeze/thaw cycles)
Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Effective November 18, 2013
|Therapeutic Range:||3-35 µg/mL|
|Toxic:||Greater than 40 µg/mL|
This test measures monohydroxyoxcarbazepine (MHD). Adverse effects may include dizziness, fatigue, nausea, headache, somnolence, ataxia and tremor.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
|Component Test Code*||Component Chart Name||LOINC|
|0098834||Oxcarb or Eslicarb Metabolite (MHD)||31019-3|
- 10-OH-Carbazepine (MHD)
- GP 47680
- Metabolite of Oxcarbazepine
- Monohydroxy Carbamazepine
- Monohydroxy Carbamazepine (MHD)
- Oxcarbazepine Metabolite
- Oxcarbazepine Metabolite, 10-Hydroxy-10
- Trileptal (Parent Pro-Drug)